Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

导出 OA

翻译打印收藏纠错

作者： Nathaniel R,West ^[1] ; Ahmed N,Hegazy ^[2] ; Benjamin M J,Owens ^[1] ; Samuel J,Bullers ^[2] ; Bryan,Linggi ^[3] ; Sofia,Buonocore ^[1] ; Margherita,Coccia ^[4] ; Dieter,Görtz ^[5] ; Sébastien,This ^[5] ; Krista,Stockenhuber ^[6] ; Johanna,Pott ^[2] ; Matthias,Friedrich ^[1] ; Grigory,Ryzhakov ^[2] ; Frédéric,Baribaud ^[5] ; Carrie,Brodmerkel ^[1] ; Constanze,Cieluch ^[1] ; Nahid,Rahman ^[4] ; Gerhard,Müller-Newen ^[4] ; Raymond J,Owens ^[7] ; Anja A,Kühl ^[8] ; Kevin J,Maloy ^[6] ; Scott E,Plevy ^[8] ; Oxford IBD Cohort Investigators ^[9] ; Satish,Keshav ^[7] ; Simon P L,Travis ^[5] ; Fiona,Powrie ^[4]

作者单位： Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. ^[1] Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK. ^[2] Somerville College, University of Oxford, Oxford, UK. ^[3] Janssen Research and Development, Raritan, New Jersey, USA. ^[4] Sir William Dunn School of Pathology, University of Oxford, Oxford, UK. ^[5] Institute of Biochemistry and Molecular Biology, RWTH Aachen University, Aachen, Germany. ^[6] Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charité-Universitätsmedizin Berlin, Germany. ^[7] OPPF-UK, The Research Complex at Harwell, Rutherford Appleton Laboratory, Harwell, Oxford, UK. ^[8] Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ^[9]